Drug interactions between antiretrovirals and hormonal contraceptives

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 5, 2013, Pages 559-572

  Tseng, Alice ^a   Hills Nieminen, Cara ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

Antiretrovirals; Drug interaction; HIV; Hormonal contraceptives; Pharmacokinetics

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; COBICISTAT; CONTRACEPTIVE AGENT; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DEPOMEDROXYPROGESTERONE; DESOGESTREL; DROSPIRENONE; EFAVIRENZ; ELVITEGRAVIR; ETHINYLESTRADIOL; ETONOGESTREL; FOSAMPRENAVIR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LEVONORGESTREL; MEDROXYPROGESTERONE ACETATE; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NORELGESTROMIN; NORETHISTERONE; NORGESTIMATE; NORGESTREL; PROGESTERONE DERIVATIVE; SAQUINAVIR; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AREA UNDER THE CURVE; DRUG METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANTI-HIV AGENTS; BENZOXAZINES; CONTRACEPTIVE AGENTS, FEMALE; DRUG INTERACTIONS; FEMALE; HIV SEROPOSITIVITY; HUMANS; MEDROXYPROGESTERONE ACETATE; NEVIRAPINE; PREGNANCY; PREGNANCY, UNPLANNED; PROTEASE INHIBITORS; RITONAVIR;

EID: 84876386689     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.772579     Document Type: Review

References (79)

1. Joint United Nations Programme on HIV/AIDS (UNAIDS). UNAIDS report on the global AIDS epidemic. World Health Organization, Geneva, Switzerland; 2012
2. Joint United Nations Programme on HIV/AIDS (UNAIDS) and World Health Organization (WHO). Global HIV/AIDS response. Epidemic update and health sector progress towards universal access. Progress report 2011. World Health Organization, Geneva, Switzerland; 2011
3. World Health Organization. Women and health: today's evidence tomorrow's agenda. World Health Organization, Geneva, Switzerland; 2009
4. Public Health Agency of Canada. At a Glance - HIV and AIDS in Canada: Surveillance Report to December 31st. Public Health Agency of Canada (PHAC), Ottawa, Canada; 2010
5. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services. Federal register 2012;1-239
6. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission. Recommendations for use of antiretroviral drugs in pregnant hiv-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Federal register 2012;1-235
7. Taylor G, Clayden P, Dhar J, et al. British HIV Association guidelines for the management of HIV infection in pregnant women. HIV Med 2012;13(Suppl 2):87-157
8. United Nations, Department of Economic and Social Affairs, Population Division (2011). World Contraceptive Use 2010 (POP/DB/CP/Rev2010)
9. World Health Organization. Sexual and reproductive health of women living with HIV/AIDS: guidelines on care, treatment and support for women living with HIV/AIDS and their children in resource-constrained settings. World Health Organization, Geneva, Switzerland; 2006 1
10. Tharao W, Logie C, James L, Loutfy M. "These are some of the things we need": women living with HIV discuss issues in their daily lives as research priorities [abstract]. Canadian Association for HIV Research Annual Conference; 14-17 April 2011; Toronto, Canada; 2011 1
11. Loutfy M, Margolese S, Money DM, et al. Canadian HIV pregnancy planning guidelines. J Obstet Gynaecol Can 2012;34(6):575-90 1
12. Oladapo OT, Daniel OJ, Odusoga OL, Ayoola-Sotubo O. Fertility desires and intentions of HIV-positive patients at a suburban specialist center. J Natl Med Assoc 2005;97:1672-81 1
13. Bristol-Myers Squibb Canada. Sustiva (efavirenz) prescribing information. Bristol-Myers Squibb Canada, Montreal, QC; 2012 1
14. World Health Organization. Technical update on treatment optimization: use of efavirenz during pregnancy: a public health perspective. World Health Organization, Geneva, Switzerland; 2012 1
15. European AIDS Clinical Society (EACS). Guidelines for the clinical management and treatment of HIV infected adults in Europe (version 6.1). European AIDS Clinical Society; 2012;1-82 1
16. Taylor S, Boffito M, Khoo S, et al. Stopping antiretroviral therapy. AIDS 2007;21:1673-82 1
17. Wang B, Sanchez RI, Franklin RB, et al. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos 2004;32(11):1209-12 1
18. Zhang H, Cui D, Wang B, et al. Pharmacokinetic drug interactions involving 17 alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 2007;46(2):133-57 1
19. Edelman AB, Cherala G, Stanczyk FZ. Metabolism and pharmacokinetics of contraceptive steroids in obese women: a review. Contraception 2010;82(4):314-23 2
20. Faculty of Sexual & Reproductive Healthcare. Drug interactions with hormonal contraception. Royal College Obstetr Gynecol 2012:1-26 2
21. Kuhl H. Comparative pharmacology of newer progestogens. Drugs 1996;51(2):188-215 2
22. Tsunoda SM, Harris RZ, Mroczkowski PJ, Benet LZ. Preliminary evaluation of progestins as inducers of cytochrome P450 3A4 activity in postmenopausal women. J Clin Pharmacol 1998;38:1137-43 2
23. Abbott Laboratories Ltd Canada. Norvir (ritonavir) prescribing information. AbbVie Corporation, Saint-Laurent, QC; 2011 2
24. Abbott Laboratories Ltd Canada. Kaletra (lopinavir/ritonavir) prescribing information. AbbVie Corporation, Saint Laurent, Canada; 2011 2
25. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metabolism & Disposition 2001;29:100-2 2
26. Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother 2008;52(5):1663-9 2
27. Foisy M, Yakiwchuk E, Hughes C. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 2008;42:1048-59 2
28. ViiV Healthcare ULC. Celsentri (maraviroc) product monograph. ViiV Healthcare ULC, Montreal, QC; 2012 2
29. Merck Frosst Canada Ltd. Isentress (raltegravir) prescribing information. Merck Frosst Canada Ltd., Kirkland, QC; 2012 3
30. Gilead Sciences, Inc. Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) Prescribing Information. Gilead Sciences, Inc., Foster City, CA: 2012 3
31. Zhang J, Chung E, Yones C, et al. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women. Antivir Ther 2011;16(2):157-64 3
32. Tackett D, Child M, Agarwala S, et al. Atazanavir: a summary of two pharmacokinetic drug interaction studies in healthy subjects [abstract 543]. 10th Conference on Retroviruses and Opportunistic Infections; 10-14 February 2003; Boston; 2003 3
33. Bristol-Myers Squibb Canada. Reyataz (atazanavir) product monograph. Bristol-Myers Squibb Canada, Montreal, QC; 2012 3
34. Sekar V, Lefebvre E, Spinosa Guzman S, al. E. Pharmacokinetic interaction between ethinyl estradiol, norethindrone and darunavir with low-dose ritonavir in healthy women. Antiviral Ther 2008;13(4):563-9 3
35. ViiV Healthcare ULC. Telzir (fosamprenavir) prescribing information. ViiV Healthcare ULC, Montreal, QC; 2011 3
36. Vogler MA, Patterson K, Kamemoto L, et al. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG Trial A5188 J Acquir Immune Defic Syndr. 2010;55(4):473-82 3
37. Pfizer Canada, Inc. Viracept (nelfinavir) product monograph. Pfizer Canada, Inc., Kirkland, QC; 2011 3
38. Boehringer Ingelheim. Aptivus (tipranavir) product monograph. Boehringer Ingelheim, Burlington, ON; 2011 3
39. Joshi AS, Fiske WD, Benedek IH, et al. Lack of a pharmacokinetic interaction between efavirenz (DMP 266) and ethinyl estradiol in healthy female volunteers [abstr 348]. 5th Conference on Retroviruses and Opportunistic Infections; 1-5 February 1998; Chicago, IL; 1998 4
40. Sinicco A, Raiteri R, Rossati A, et al. Efavirenz interference in estradiol ELISA assay. Clin Chem 2000;46:734-5 4
41. Sevinsky H, Eley T, He B, et al. Effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women. Antivir Ther 2011;16(2):149-56 4
42. Landolt NK, Phanuphak N, Ubolyam S, et al. Efavirenz, in contrast to nevirapine, is associated with unfavorable progesterone and antiretroviral levels when co-administered with combined oral contraceptives. J Acquir Immune Defic Syndr 2012;Epub ahead of print 4
43. Carten M, Kiser J, Kwara A, et al. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel (Plan B), and efavirenz. Infect Dis Obstet Gynecol 2012; Epub 2012 Feb 28 4
44. Mildvan D, Yarrish R, Marshak A, et al. Pharmacokinetic interaction between nevirapine and ethinyl estradiol/ norethindrone when administered concurrently to HIV-infected women. Journal of the Acquired Immune Deficiency Syndrome 2002;29:471-7 4
45. Boehringer Ingelheim (Canada) Ltd. Viramune and viramune XR (nevirapine) product monograph. Boehringer Ingelheim, Burlington, ON; 2011 4
46. Stuart G, Moses A, Corbett A, et al. Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi. J Acquir Immune Defic Syndr 2011;58(2):e40-3 4
47. Nanda K, Delany-Moretlwe S, Dube K, et al. Nevirapine-containing ART does not reduce combined oral contraceptive effectiveness: results from South Africa and Uganda [abstract O-03]. 3rd International Workshop on HIV & Women; 14-15 January 2013; Toronto, Canada; 2013 4
48. Scholler-Gyure M, Kakuda TN, Woodfall B, et al. Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone. Contraception 2009;80(1):44-52 4
49. Crauwels HM, Van Heeswijk R, Cornelis L, et al. Pharmacokinetic interaction study between TMC278, an NNRTI, and the contraceptives norethindrone plus ethinylestradiol [abstract PE 4.3/3]. 12th European AIDS Conference; 11-14 November 2009; Cologne: Germany: 2009 5
50. Abel SR, Russell D, Whitlock L, et al. Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/ levonorgestrel in healthy volunteers. Br J Clin Pharmacol 2008;65(Suppl 1):19-26 5
51. Anderson MS, Hanley WD, Moreau A, et al. Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. Br J Clin Pharmacol 2011;71(4):616-20 5
52. German P, Wang M, Warren D, Kearney BP. Pharmacokinetic interaction between norgestimate/ethinyl estradiol and elvitegravir/cobicistat/ emtricitabine/ tenofovir single tablet regimen [abstract O-17]. 12th International Workshop on Clinical Pharmacology of HIV Therapy; 13-15th April 2011; Miami, USA; 2011 5
53. Kearney BP, Mathias A. Lack of effect of tenofovir disoproxil fumarate on pharmacokinetics of hormonal contraceptives. Pharmacother 2009;29(8):924-9 5
54. Lakhi N, Govind A. Implanon- failure in patients on antiretroviral medication: the importance of disclosure. J Fam Plann Reprod Health Care 2010;36(3):181 5
55. Leticee N, Viard JP, Yamgnane A, et al. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals including efavirenz. Contraception 2012;85(4):425-7 5
56. McCarty EJ, Keane H, Quinn K, Quah S. Implanon- failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies. Int J Std AIDS 2011;22(7):413-14 5
57. Matiluko AA, Soundararjan L, Hogston P. Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. J Fam Plann Reprod Health Care 2007;33(4):277-8 5
58. Kreitchmann R, Innocente AP, Preussler GM. Safety and efficacy of contraceptive implants for HIV-infected women in Porto Alegre. Brazil. Int J Gynaecol Obstet 2012;117(1):81-2 5
59. Crauwels HM, Van Heeswijk R, Stevens T, et al. The effect of TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) on CYP3A activity in vivo [abstract P-28]. 10th International Workshop on Clinical Pharmacology of HIV Therapy; 15-17 April 2009; Amsterdam; 2009 6
60. Janssen, Inc. Edurant (rilpivirine). Product Monograph. Janssen, Inc., Toronto, ON; 2011 6
61. Cohn SE, Park JG, Watts DH, et al. Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions. Clin Pharmacol Ther 2007;81(2):222-7 6
62. Watts DH, Park JG, Cohn SE, et al. Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A509. Contraception 2008;77(2):84-90 6
63. Nanda K, Amaral E, Hays M, et al. Pharmacokinetic interactions between depot medroxyprogesterone acetate and combination antiretroviral therapy. Fertil Steril 2008;90(4):965-71 6
64. Heikinheimo O, Lehtovirta P, Suni J, Paavonen J. The levonorgestrel- releasing intrauterine system (LNG-IUS) in HIV-infected women-effects on bleeding patterns, ovarian function and genital shedding of HIV. Hum Reprod 2006;21(11):2857-61 6
65. Heikinheimo O, Lehtovirta P, Aho I, et al. The levonorgestrel-releasing intrauterine system in human immunodeficiency virus infected women: a 5-year follow-up study. Am J Obstet Gynecol 2011;204(2):126.e1-4 6
66. Centers for Disease Control and Prevention. Update to CDC's U. S. Medical Eligibility Criteria for Contraceptive Use, 2010: Revised Recommendations for the Use of Hormonal Contraception Among Women at High Risk for HIV or infected with HIV. MMWR. US Department of Health and Human Services, 2012;61(24):449-52 6
67. Walker Harris V, Brown TT. Bone loss in the HIV-infected patient: evidence, clinical implications, and treatment strategies. J Infect Dis 2012;205(Suppl 3):S391-8 6
68. Pfizer Canada, Inc. Depo-provera (medroxyprogesterone acetate injectable suspension) product monograph. Pfizer Canada, Inc., Kirkland, QC; 2011 6
69. Nappi C, Bifulco G, Tommaselli GA, et al. Hormonal contraception and bone metabolism: a systematic review. Contraception 2012;86:606-21 7
70. Lopez LM, Grimes DA, Schulz KF, Curtis KM. Steroidal contraceptives: effect on bone fractures in women. Cochrane Database Syst Rev 2011;6:7 7
71. Black A, Dunn S, Guilbert E ́, et al. Canadian Contraception Consensus-Update on depot medroxyprogesterone acetate (DMPA). J Obstet Gynaecol Can 2006;28(4):305-8 7
72. Janssen, Inc. Prezista (darunavir) product monograph. Toronto, Ontario: 2011 7
73. Merck Frosst Canada Ltd. Crixivan (indinavir) product monograph. Merck Frosst Canada Ltd., Kirkland, QC; 2012 7
74. Hoffmann-La Roche Ltd. Invirase (saquinavir) product monograph. Hoffmann-La Roche Ltd., Mississauga, ON; 2012 7
75. Robertson SM, Maldarelli F, Natarajan V, et al. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr. Lippincott Williams & Wilkins, Inc., 2008;49(5):513-19 7
76. Lee L, Soon GH, Shen P, et al. Effect of efavirenz and darunavir/ritonavir on bilirubin levels in healthy adult volunteers: role of induction of UGT1A1 and bile efflux transporters [abstract 27]. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 5-7 April 2010; Sorrento, Italy; 2010 7
77. Janssen, Inc. Intelence (etravirine). product monograph. Toronto, ON: 2011 7
78. Hughes CA, Foisy M, Tseng A. Interactions between antifungal and antiretroviral agents. Expert Opin Drug Saf. Informa Healthcare, 2010;9(5):723-42 7
79. Frohlich M, Burhenne J, Martin-Facklam M, et al. Oral contraception does not alter single dose saquinavir pharmacokinetics in women. Br J Clin Pharmacol 2004;57(3):244-52